AstraZeneca Investor Day Presentation Deck

Enhertu in breast cancer and beyond Opportunities across treatment settings HER2-positive breast cancer HER2-low breast cancer Beyond breast cancer neo-adjuvant / adjuvant post neo-adjuvant neo-adjuvant replace chemo + trastuzumab + pertuzumab replace T-DM1 adjuvant replace chemo + trastuzumab + pertuzumab HR+: chemotherapy ± endocrine therapy 1st-line metastatic replace chemotherapy + trastuzumab + pertuzumab HR-: chemotherapy +/- 10 endocrine + CDK4/6i 2nd-line metastatic replace T-DM1 and other standard of care 3rd-line metastatic replace/displace chemotherapy and endocrine combinations¹ replace/displace chemotherapy and evaluate combinations broaden in gastric cancer and expand into NSCLC, CRC and other cancers 21 HR = hormone-receptor positive; CDK4/6i = cyclin-dependent kinase 4/6 inhibitor; HR- = hormone-receptor negative; 10 = immuno-oncology. NSCLC = non-small cell lung cancer; CRC = colorectal cancer. 1. in endocrine therapy refractory/resistant patients. A

View entire presentation